Processa Pharmaceuticals (PCSA) Stock Forecast, Price Target & Predictions
PCSA Stock Forecast
Processa Pharmaceuticals stock forecast is as follows: an average price target of $9.00 (represents a 710.81% upside from PCSA’s last price of $1.11) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
PCSA Price Target
PCSA Analyst Ratings
Processa Pharmaceuticals Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Apr 19, 2022 | - | Maxim Group | $9.00 | $3.18 | 182.62% | 710.81% |
Processa Pharmaceuticals Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $1.11 | $1.11 | $1.11 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Jan 12, 2023 | Maxim Group | Buy | Buy | Hold |
Aug 03, 2021 | Oppenheimer | - | Outperform | Initialise |
Processa Pharmaceuticals Financial Forecast
Processa Pharmaceuticals Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Processa Pharmaceuticals EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Processa Pharmaceuticals Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - |
Avg Forecast | $-1.57M | $-1.54M | $-1.80M | $-2.16M | $-2.49M | $-3.28M | $-3.01M |
High Forecast | $-1.57M | $-1.54M | $-1.80M | $-2.16M | $-2.49M | $-3.28M | $-3.01M |
Low Forecast | $-1.57M | $-1.54M | $-1.80M | $-2.16M | $-2.49M | $-3.28M | $-3.01M |
Surprise % | - | - | - | - | - | - | - |
Processa Pharmaceuticals SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Processa Pharmaceuticals EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - |
Avg Forecast | $-0.48 | $-0.47 | $-0.55 | $-0.66 | $-0.76 | $-1.00 | $-1.01 |
High Forecast | $-0.48 | $-0.47 | $-0.55 | $-0.66 | $-0.76 | $-1.00 | $-1.01 |
Low Forecast | $-0.48 | $-0.47 | $-0.55 | $-0.66 | $-0.76 | $-1.00 | $-1.01 |
Surprise % | - | - | - | - | - | - | - |
Processa Pharmaceuticals Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
AKTX | Akari Therapeutics | $2.43 | $12.00K | 493727.16% | - |
PMVP | PMV Pharmaceuticals | $1.64 | $24.75 | 1409.15% | Buy |
PCSA | Processa Pharmaceuticals | $1.11 | $9.00 | 710.81% | Buy |
ANTX | AN2 Therapeutics | $1.08 | $8.75 | 710.19% | Buy |
FENC | Fennec Pharmaceuticals | $4.65 | $15.75 | 238.71% | Buy |
ANEB | Anebulo Pharmaceuticals | $1.89 | $6.00 | 217.46% | Buy |
ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
CELC | Celcuity | $15.36 | $31.50 | 105.08% | Buy |
IKT | Inhibikase Therapeutics | $2.61 | $5.00 | 91.57% | Buy |
SABS | SAB Biotherapeutics | $4.04 | $5.67 | 40.35% | Buy |
THRD | Third Harmonic Bio | $12.11 | $16.15 | 33.36% | Buy |
ELVN | Enliven Therapeutics | $27.65 | $35.50 | 28.39% | Buy |
PCSA Forecast FAQ
Is Processa Pharmaceuticals a good buy?
Yes, according to 3 Wall Street analysts, Processa Pharmaceuticals (PCSA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of PCSA's total ratings.
What is PCSA's price target?
Processa Pharmaceuticals (PCSA) average price target is $9 with a range of $9 to $9, implying a 710.81% from its last price of $1.11. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Processa Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for PCSA stock, the company can go up by 710.81% (from the last price of $1.11 to the average price target of $9), up by 710.81% based on the highest stock price target, and up by 710.81% based on the lowest stock price target.
Can Processa Pharmaceuticals stock reach $2?
PCSA's average twelve months analyst stock price target of $9 supports the claim that Processa Pharmaceuticals can reach $2 in the near future.
What are Processa Pharmaceuticals's analysts' financial forecasts?
Processa Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-8.779M (high $-8.779M, low $-8.779M), average SG&A $0 (high $0, low $0), and average EPS is $-2.77 (high $-2.77, low $-2.77). PCSA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-7.076M (high $-7.076M, low $-7.076M), average SG&A $0 (high $0, low $0), and average EPS is $-2.16 (high $-2.16, low $-2.16).